Argenx SE (ARGX) shares plummeted 7.09% during intraday trading on Thursday, marking a significant downturn for the biopharmaceutical company.
The sharp decline followed the company's report of a year-over-year decrease in its fourth-quarter earnings. Despite beating analyst expectations, Argenx's Q4 earnings per share fell to $8.02 from $11.79 in the same period last year.
This earnings decline appears to be the primary driver behind the negative investor sentiment and the substantial sell-off observed during the trading session.